Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gemcitabine + suramin
- Development stage
- Unknown
- Lead developer
- Eli Lilly
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
A combination therapy consisting of gemcitabine, a nucleoside metabolic inhibitor, and suramin, a non-cytotoxic agent used as a chemotherapy modulator. In preclinical models, non-cytotoxic suramin at concentrations <50 µM has been shown to potentiate the activity of multiple chemotherapeutic agents including gemcitabine. This combination has been studied in Phase I trials for previously chemotherapy-treated patients with advanced non-small cell lung cancer.
02
Targets
DNA polymerase familyRNR (Ribonucleotide reductase)ELAVL1 (Human Antigen R)
Beyond the preview
Go deeper on gemcitabine + suramin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gemcitabine + suramin.